SANTA
CLARA, Calif., July 22,
2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq:
SMLR), a pioneer in developing and marketing technology products
and services to healthcare providers to combat chronic diseases,
today announced that it will report financial results for the
second quarter and six months ended June 30,
2024, after the close of U.S. financial markets on
Monday, August 5, 2024. Doug Murphy-Chutorian, M.D., chief executive
officer of Semler Scientific, will host a conference call at
4:30 pm ET the same day. Eric Semler, chairman, Renae Cormier, chief financial officer, and
Jennifer Oliva-Herrington, chief
operating officer, will join him on the call. Please submit
questions prior to the start of the call to
ir@semlerscientific.com.
We encourage participants to pre-register for the conference
call using the following
link: https://dpregister.com/sreg/10190580/fcfdde76dc. Callers
who pre-register will be given a conference passcode and unique PIN
to gain immediate access to the call and bypass the live operator.
Participants may pre-register at any time, including up to and
after the call start time.
Those without internet access or unable to pre-register may dial
in by calling:
Domestic callers: 833-816-1161
International callers: 412-317-0717
Please specify to the operator that you would like to join the
"Semler Scientific Call." The conference call will be archived on
Semler Scientific's website at www.semlerscientific.com.
About Semler Scientific, Inc.:
Semler Scientific,
Inc. develops, manufactures and markets innovative products and
services to combat chronic diseases. Its flagship product,
QuantaFlo®, which is patented and cleared by the U.S.
Food and Drug Administration (FDA), is a rapid point-of-care test
that measures arterial blood flow in the extremities. The QuantaFlo
test aids in the diagnosis of cardiovascular diseases, such as
peripheral arterial disease (PAD), and Semler Scientific is seeking
a new 510(k) clearance for expanded-indications. QuantaFlo is used
by healthcare providers to evaluate their patient's risk of
mortality and major adverse cardiovascular events (MACE). Semler
Scientific also invests in bitcoin and has adopted
bitcoin as its primary treasury asset. Additional
information about Semler Scientific can be found at
www.semlerscientific.com.
CONTACT:
Renae Cormier, CFO
ir@semlerscientific.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-scientific-to-report-second-quarter-and-first-half-of-2024-financial-results-and-host-conference-call-on-august-5-2024-302203104.html
SOURCE Semler Scientific, Inc.